


Japan data and OHDSI Japan





(Cross hospital)

All patients data



Major Japanese databases in Japan available for clinical/pharmaco-epidemiology(1)

Hospital-based

DB name	admin	# uniq ID	Data Source	
MID-NET	PMDA	>5M	SS-MIX2, DPC, Claims	High Quality
EBM Provider	MDV Co.,Ltd.	30M	DPC, Claims, Lab, others	Major in HB
RWD-DB	RWD Co.,Ltd.	20M	DPC, Claims, EMR, Lab	
MIA	NHO	20M	DPC, Claims	1 stop service
NCD	NCD	12M	Surgery information	
JMDC C. DB	JMDC	8.8M	DPC, Claims	
NCDA	NHO	1.9M	SS-MIX2, Lab, etc.	1 stop service

Reference:

Pharmacoepidemiology & Database Taskforce, Japanese Society for Pharmacoepidemiology. Survey of Japanese databases in Japan available for clinical/pharmacoepidemiology.



Major Japanese databases in Japan available for clinical/pharmaco-epidemiology(2)

Insurance-based

DB name	admin	# uniq ID	Data Source	
NDB	MHLW	All Patients	Claims	The Big One
JMDC C. DB	JMDC	7.4M	Claims	Major in IB
MinaCare	MinaCare	6.3M	Claims, others.	
Medi-Scope	Kyowa Kikaku	6.6M	Claims, others	

Reference:

Pharmacoepidemiology & Database Taskforce, Japanese Society for Pharmacoepidemiology. Survey of Japanese databases in Japan available for clinical/pharmacoepidemiology.



Major Japanese databases in Japan available for clinical/pharmaco-epidemiology(3)

Pharmacy-based

DB name	admin	# uniq ID	Data Source
IQVIA NPA	IQVIA Sol. JP	32M	Pharmacy Claims
JMIRI	JMIRI	39M	Pharmacy Claims
Medi-Trend	Kyowa Kikaku	6.5M	Pharmacy Claims
NihonChouzai	Nihon-Chouzai	16M	Pharmacy Claims, others
PFR	PFR(CCT K.K.)	8.2M	Pharmacy Claims

Reference:

Pharmacoepidemiology & Database Taskforce, Japanese Society for Pharmacoepidemiology. Survey of Japanese databases in Japan available for clinical/pharmacoepidemiology.



Act on the Protection of Personal Information

in Japan

Passing PHI to third parties is highly restricted.

- Individual agreement \rightarrow OK
- Gov's execution under a low \rightarrow OK (without individual agreement)
- Opt-out permission ightarrow forbidden for PHI
- Usual anonymized data → Virtually impossible (Most anonymized data are possible to identify individuals by matching with some additional information)

Instead, "TOKUMEI KAKOU" (anonymous processing) is provided in the PIP low.

- By following specific procedures and rules, anonymized data can be passed.
- Identifying individuals is banned.



Medical Big Data Law

"Next Generation Medical Infrastructure Act"

- It partially overwrites the PIP act.
- Certified corporations can collect non-anonymized PHI from hospitals with the "careful opt-out" permission.
- These corporations are allowed to merge the data using personal identifiers and pass the extracted TOKUMEI KAKOU data to third parties.
- The first operator is finally certified in Dec. 2019.





OHDSI Japan



1st Meeting June 20th ,2019



2nd Meeting Sep 5th - 6th,2019

> Mini-meet #1 Oct 29, 2019

3rd Meeting Nov 19th ,2019

> Mini-meet #2 Dec 17, 2019

Mini-meet #3 Jan 21, 2020






<u>Main attendee affiliations</u>: University hospitals, Pharmaceutical companies, IT vendors, Data vendors



Multi-stage OMOPize method with useful intermediate stage data.





JOMOPie – features

1. Field expansion in clinical data tables for multiple Japanese standard codes, which is not for global use but is for domestic use where compatibility with other Japanese databases is important. Vocab tables are intact.


* *_source_value fields are for original local codes/names.

- *_concept_id fields whose corresponding extended fields have values can be left as empty (or zero) for domestic use.
 * Therefore, SNOMED issues can be set aside. Japan is not SNOMED member.
 ->Data holders in Japan are easy to participate
- 4. Limitation: Standard tools such as Atlas cannot be used without filling required *_concept_id fields.




A free ETL tool in Japan

Prof Hiramatsu has developed a tool that can easily perform ETL using Oracle VirtualBox virtual machine.



⅔ JV is the previous version of JOMOPie. We are going to reconstruct the tool.

An Example of usage in Japan





As OHDSI JAPAN, we would like to realize the spread of OMOP in Japan by promoting activities such as...

- > Translating "The book of OHDSI"
- Conducting various seminars
- Promoting implementation with Real data holders

...etc

We really look forward to make new evidence with global healthcare data together with you!

> Asia-Pasific Symposium 2020 Dec. 2020, Shanghai